Eduardo Sotomayor, MD: I am using ibrutinib with rituximab in patients with mantle cell lymphoma with a low-proliferation index. It was based on data from Michael Wang from The University of Texas MD Anderson Cancer Center in which he shows that the addition of rituximab to ibrutinib increases our complete response rate, CR rate, but again, in this specific population with a low-proliferation index. I might need to revisit that. Again, we cannot extrapolate data from one disease to the other, but there is now clearly an indication that in chronic lymphocytic leukemia [CLL], the addition of rituximab doesn

Transcript:

Eduardo Sotomayor, MD: I am using ibrutinib with rituximab in patients with mantle cell lymphoma with a low-proliferation index. It was based on data from Michael Wang from The University of Texas MD Anderson Cancer Center in which he shows that the addition of rituximab to ibrutinib increases our complete response rate, CR rate, but again, in this specific population with a low-proliferation index. I might need to revisit that. Again, we cannot extrapolate data from one disease to the other, but there is now clearly an indication that in chronic lymphocytic leukemia [CLL], the addition of rituximab doesn